GABAA-Modulating Steroid Regimen for Episodic Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS-related disorders such as depression, including postpartum depression and major depressive disorder, require extended and often chronic administration, posing challenges in patient compliance and potential side effects.
Innovation Solution
Administering Compound 1, a positive allosteric modulator of GABAA receptors, using an episodic dosing regimen that involves administering the compound for a specified period, followed by a break, to effectively treat depression without chronic dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chronic treatment regimens are used for depression, then therapeutic effectiveness is maintained, but patient compliance deteriorates and side effects increase
Solution Approach 1:
The patent implements periodic action by transitioning from continuous chronic dosing to episodic dosing regimens. Treatment is administered in discrete time-limited periods (e.g., 2-6 weeks) followed by drug-free intervals, creating a periodic pattern that maintains therapeutic effectiveness while reducing long-term compliance burden and side effects.
Solution Approach 2:
The treatment regimen is segmented into distinct episodic phases rather than continuous administration. Each episode consists of an active treatment period followed by a cessation period, dividing the overall treatment into manageable segments that improve patient compliance while maintaining reliability through targeted intervention during depressive episodes.
2Reliability
If chronic treatment regimens are used for depression, then therapeutic effectiveness is maintained, but the number of administrations increases and side effects worsen
Solution Approach 1:
Periodic action reduces the quantity of substance administered by implementing treatment only during specific episodic periods rather than continuously. The periodic dosing pattern creates drug-free intervals that reduce cumulative administration volume while maintaining effectiveness during active depressive episodes.
Solution Approach 2:
The patent applies partial action by providing treatment only when needed (during depressive episodes) rather than continuously. This selective administration reduces the total quantity of drug administered while maintaining therapeutic effectiveness during the partial periods when depression is present.
3Reliability
If extended treatment periods are used, then therapeutic effectiveness is improved, but loss of time and patient burden increase
Solution Approach 1:
Periodic action addresses the time loss contradiction by implementing time-limited episodic treatment periods (2-6 weeks) followed by drug-free intervals. This periodic pattern reduces overall treatment time compared to chronic continuous administration while maintaining therapeutic effectiveness during the active treatment phases.
Solution Approach 2:
The treatment regimen transitions from a static chronic model to a dynamic episodic model that adapts to patient needs. The dynamic structure allows treatment duration to be adjusted based on depressive episode severity and response, optimizing the balance between therapeutic effectiveness and time investment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The episodic dosing regimen provides effective treatment with fewer administrations, reduces side effects, and improves cognitive function, offering a more convenient and patient-friendly approach compared to traditional chronic therapies.
Implementation Method 1
Compound 1, a neuroactive steroid described herein, has been shown to be a positive allosteric modulator of GABAA receptors that targets synaptic and extrasynaptic GABAA receptors
Implementation Method 2
GABA interacts with its recognition site on the GRC (GABA receptor complex) to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell
Implementation Method 3
An intracellular increase in the levels of this anion causeshyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs
Data Source
AI summary
Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof: